Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Fate Therapeutics Inc (NASDAQ:FATE)

3.38
Delayed Data
As of 4:00pm ET
 +0.21 / +6.62%
Today’s Change
1.55
Today|||52-Week Range
5.68
+34.66%
Year-to-Date
No recent news for Fate Therapeutics Inc.

Today’s Trading

Previous close3.17
Today’s open3.19
Day’s range3.11 - 3.38
Volume230,400
Average volume (3 months)404,509
Market cap$131.2M
Dividend yield--
Data as of 4:00pm ET, 06/28/2017

Growth & Valuation

Earnings growth (last year)+11.02%
Earnings growth (this year)+5.14%
Earnings growth (next 5 years)--
Revenue growth (last year)+81.08%
P/E ratioNM
Price/Sales18.11
Price/Book1.79

Competitors

 Today’s
change
Today’s
% change
PSTIPluristem Therapeuti...-0.02-1.48%
EVGNEvogene Ltd+0.05+0.97%
AXSMAxsome Therapeutics ...+0.35+6.42%
VBLTVascular Biogenics L...+0.05+1.08%
Data as of 4:00pm ET, 06/28/2017

Financials

Next reporting dateAugust 8, 2017
EPS forecast (this quarter)-$0.24
Annual revenue (last year)$4.4M
Annual profit (last year)-$33.5M
Net profit margin-760.15%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
J. Scott Wolchko
Chief Scientific Officer
Daniel D. Shoemaker
Corporate headquarters
San Diego, California

Forecasts